Haoxi Health Technology Limited (HAO) AI Stock Analysis
HAO AI stock analysis summary
AI ResearchHaoxi Health Technology Limited provides online marketing solutions primarily for healthcare advertisers in China. In FY2025, revenue fell 32.4% to $32.8M, though trailing twelve-month revenue reached $54.8M through June 30, 2026. The company holds net cash of $9.3M against a market capitalization of $772,525.
- Market cap
- $772,525
- Revenue (TTM)
- $54.8M
- P/E
- —
- 1Y return
- — S&P 500 16.8%
- Avg. target
- —
Bull case
- Quarterly revenue grew 137.3% year-over-year in the latest quarter ended June 30, 2026.
- The balance sheet maintains net cash of $9.3M and a current ratio of 4.53 as of June 30, 2026.
- Five-year revenue expanded at a compound annual growth rate of 20.6% from FY2020 to FY2025.
Bear case
- Free cash flow has remained negative across all reported annual periods, reaching -$3.4M in FY2025.
- Trailing twelve-month profit margin is -17.4%, resulting in diluted earnings per share of -$386.40.
- The stock closed at $2.11 on October 16, 2026, representing a steep decline from its 52-week high of $169.98.
What Haoxi Health Technology does
Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. The company delivers online short video marketing solutions to advertisers through its media partners, as well as customized marketing solutions that include planning, producing, placing, and optimizing online advertisements. These solutions help advertisers acquire, convert, and retain consumers across mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Weibo. Its client base is primarily concentrated in the healthcare industry. Founded in 2018 and based in Chaoyang, China, the business operates with 28 employees.
Growth and profitability
Haoxi Health Technology's revenue grew from $16.2M in FY2021 to $48.5M in FY2023, reflecting a five-year revenue compound annual growth rate of 20.6% from FY2020 to FY2025. In FY2025, revenue fell 32.4% to $32.8M, operating margin was -6.1%, and net income reached $3.9M, representing a net margin of 11.8%. For the trailing twelve months ended June 30, 2026, revenue totaled $54.8M alongside an operating margin of -11.8% and a profit margin of -17.4%. During the latest quarter ended June 30, 2026, quarterly revenue increased 137.3% year-over-year, and quarterly earnings grew 172.7%.
Balance sheet and cash flow
As of June 30, 2026, the company held $10.9M in cash and short-term investments and $1.6M in total debt, resulting in net cash of $9.3M. Total assets stood at $21.6M compared to shareholders' equity of $17.9M, yielding a debt-to-equity ratio of 0.09 and a current ratio of 4.53. In FY2025, operating cash flow was -$3.4M and free cash flow was -$3.4M, with capital expenditures of $2. The company's share count changed by -98.9% over five years.
Valuation and performance
Haoxi Health Technology has a market capitalization of $772,525 and an enterprise value of -$4.0M. The stock trades at an EV/EBITDA of 13.5x, above the 10.0x median of its US-listed Communication Services peers. Its price-to-sales ratio is 0.0x compared to the peer median of 0.8x, and its price-to-book ratio is 0.1x. The shares last closed at $2.11 on October 16, 2026, near their 52-week low of $2.09 and below their 52-week high of $169.98. The stock has a beta of -1.08, while the S&P 500 (SPY) returned 16.8% over the past year and 83.0% over five years.
What analysts expect
There are no analyst rating counts, consensus recommendations, or price targets published for Haoxi Health Technology. Revenue and earnings estimates are not available, and an upcoming earnings date is not scheduled. Over the trailing twelve months ended June 30, 2026, the company reported diluted earnings per share of -$386.40, while quarterly earnings grew 172.7% year-over-year in the latest reported quarter.
Key risks and what to watch
- Annual operating cash flow deteriorated to -$3.4M in FY2025, reflecting continued operational cash burn.
- The trailing twelve-month operating margin of -11.8% sits well below the US-listed Communication Services peer median of 13.3%.
- Annual revenue contracted 32.4% in FY2025 to $32.8M, demonstrating top-line volatility.
- With a market capitalization of $772,525 and institutional ownership of 0.5%, the stock carries micro-cap liquidity characteristics.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this HAO AI stock analysis
This page is an AI-written research summary of Haoxi Health Technology Limited (HAO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: HAO income statement, HAO balance sheet, HAO key metrics, HAO chart. See the HAO stock overview for the latest quote and news.
HAO AI stock analysis FAQ
What does Haoxi Health Technology Limited do?
Haoxi Health Technology Limited provides online short video and customized digital marketing solutions in China. It places ads on major platforms like Douyin, Toutiao, WeChat, and Weibo, serving clients primarily in the healthcare sector.
What is Haoxi Health Technology's cash position?
As of June 30, 2026, the company held $10.9M in cash and short-term investments against $1.6M in total debt, leaving it with net cash of $9.3M.
Does Haoxi Health Technology pay a dividend?
Haoxi Health Technology does not pay a dividend.
How does Haoxi Health Technology's valuation compare to its sector?
Haoxi Health Technology trades at an EV/EBITDA multiple of 13.5x, higher than the median of 10.0x for its US-listed Communication Services peers, but has a price-to-sales multiple of 0.0x compared to the peer median of 0.8x.